ID Source | ID |
---|---|
PubMed CID | 71227 |
CHEMBL ID | 1742448 |
SCHEMBL ID | 1254721 |
MeSH ID | M0131905 |
Synonym |
---|
adimolol |
3-[3-[(2-hydroxy-3-naphthalen-1-yloxypropyl)amino]-3-methylbutyl]-1h-benzimidazol-2-one |
78459-19-5 |
CHEMBL1742448 |
(+-)-1-(3-((2-hydroxy-3-(1-naphthyloxy)propyl)amino)-3-methylbutyl)-2-benzimidazolinone |
adimolol [inn] |
b6cjy5k2st , |
adimololum [latin] |
unii-b6cjy5k2st |
adimololum |
(rs)-2,3-dihydro-1-(3-(2-hydroxy-3-(naphthyloxy)propylamino)-3-methylbutyl)-1h-2-benzimidazolon |
adimolol [mart.] |
(+/-)-1-(3-((2-hydroxy-3-(1-naphthyloxy)propyl)amino)-3-methylbutyl)-2-benzimidazolinone |
SCHEMBL1254721 |
Q4682859 |
1,3-dihydro-1-[3-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]-3-methylbutyl]-2h-benzimidazol-2-one |
1-(3-((2-hydroxy-3-(1-naphthyloxy)propyl)amino)-3-methylbutyl)-2-benzimidazolinone |
DTXSID00868480 |
Adimolol is a new antihypertensive agent with strong nonselective beta- and moderate alpha-adrenolytic properties.
Excerpt | Reference | Relevance |
---|---|---|
"Adimolol is a new antihypertensive agent with strong nonselective beta- and moderate alpha-adrenolytic properties. " | ( Blood pressure lowering action and alpha-adrenolytic effect of adimolol in rats. Hoefke, W; Palluk, R, ) | 1.81 |
Excerpt | Reference | Relevance |
---|---|---|
"The pharmacokinetic properties of adimolol (MEN 935), a new antihypertensive agents with predominantly beta-receptor blocking and additional alpha-adrenolytic activity were investigated in healthy volunteers." | ( Pharmacokinetics of adimolol after single and multiple dose administration in healthy volunteers. Adamus, S; Brantl, V; Justus, H; Lohmann, H; Peil, H; Wiedemann, I, 1985) | 0.87 |
Excerpt | Relevance | Reference |
---|---|---|
" Labetalol 400 mg significantly shifted the blood pressure dose-response curve to the right." | ( Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man. Harron, DW; Riddell, JG; Shanks, RG, 1985) | 0.58 |
" In addition, adimolol significantly reduced receptor number and even by 3 days after dosing Bmax had only returned to half the control value." | ( Adimolol, a long acting beta-adrenoceptor blocker in man. Deighton, NM; Elliott, HL; Jones, CR; Meredith, PA; Reid, JL, 1987) | 2.08 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (33.33%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (66.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |